Clinical
Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.
6 signals
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
CLINICAL
SillaJen is conducting Phase 1 trial of BAL0891, evaluating its safety and tolerability in advanced solid tumors and relapsed/refractory AML.
CLINICAL
A phase I/II trial (ScarASC) is underway to evaluate the efficacy of allogeneic adipose-derived stem cells for treating hypertrophic scars in burn survivors.
CLINICAL
Lilly's AJ1-11095, a type II JAK2 inhibitor, shows an encouraging safety profile and promising clinical activity in myelofibrosis patients.
CLINICAL
The Phase 1/2 trial demonstrated that GSK's AS03-adjuvanted H5N8 vaccine met FDA immunogenicity criteria, with higher immune responses in younger adults.
STRATEGY
COVAC-2, a recombinant protein vaccine, demonstrated a favorable safety profile and strong immune responses as a booster in previously vaccinated adults.
CLINICAL
A first-in-human phase I/IIa trial is evaluating the safety and efficacy of [212Pb]VMT01, an alpha-particle therapy, in combination with nivolumab for advanced melanoma.
Showing 1–6 of 6 records